This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%
by Zacks Equity Research
Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Bristol-Myers (BMY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Bristol-Myers (BMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Bristol-Myers (BMY) Is a Great Growth Stock
by Zacks Equity Research
Bristol-Myers (BMY) could produce exceptional returns because of its solid growth attributes.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
Bristol-Myers (BMY) Beats on Q2 Earnings & Sales, Raises View
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the second quarter, primarily on robust sales of Opdivo and Eliquis. However, pipeline setbacks are a concern.
Bristol-Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) delivered earnings and revenue surprises of 11.32% and 3.86%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Is a Beat in the Cards for Celgene's (CELG) Q2 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the acquisition by Bristol-Myers, when Celgene Corporation (CELG) reports Q2 results.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
by Zacks Equity Research
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
by Zacks Equity Research
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.
Top Research Reports for Abbott, Netflix & Philip Morris
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Netflix (NFLX) and Philip Morris (PM).
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Bristol-Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
by Ekta Bagri
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study
by Zacks Equity Research
Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed at $44.19 in the latest trading session, marking a -0.18% move from the prior day.
Will Bristol-Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Drug Pricing Woes Linger on Repealing Drug Rebate Proposal
by Zacks Equity Research
Investors' skepticism runs rife as Trump drops the drug rebate proposal, pushing drugmakers to take center stage with regard to the controversial drug pricing issue.
AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC
by Zacks Equity Research
The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.